CN114209669A - Sustained-release preparation and preparation method and application thereof - Google Patents
Sustained-release preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN114209669A CN114209669A CN202210108925.2A CN202210108925A CN114209669A CN 114209669 A CN114209669 A CN 114209669A CN 202210108925 A CN202210108925 A CN 202210108925A CN 114209669 A CN114209669 A CN 114209669A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- sustained
- polyvinylpyrrolidone
- preparation
- release preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003405 delayed action preparation Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 111
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 76
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 56
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 50
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 50
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 50
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 45
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 45
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 45
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 36
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 32
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 28
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims abstract description 15
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 47
- 239000003826 tablet Substances 0.000 claims description 42
- 239000008187 granular material Substances 0.000 claims description 41
- 238000002156 mixing Methods 0.000 claims description 32
- 239000010410 layer Substances 0.000 claims description 30
- 238000007873 sieving Methods 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000013268 sustained release Methods 0.000 claims description 19
- 239000012730 sustained-release form Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 16
- 239000011118 polyvinyl acetate Substances 0.000 claims description 16
- 206010020772 Hypertension Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 11
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 11
- 238000007906 compression Methods 0.000 claims description 10
- 230000006835 compression Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 6
- 230000008816 organ damage Effects 0.000 claims description 6
- 239000002356 single layer Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 13
- 238000004090 dissolution Methods 0.000 description 24
- 230000002496 gastric effect Effects 0.000 description 18
- 230000014759 maintenance of location Effects 0.000 description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 15
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 229960001375 lactose Drugs 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 102220538345 Putative stereocilin-like protein_K35M_mutation Human genes 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003021 heart conduction system Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[(2r,3s,4r,5r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 1
- UFMLXCNESJKXFY-UHFFFAOYSA-N 3-[4-[4-(benzotriazol-1-yl)butyl]piperazin-1-yl]-1,2-benzothiazole hydrochloride Chemical compound C1CN(CCN1CCCCN2C3=CC=CC=C3N=N2)C4=NSC5=CC=CC=C54.Cl UFMLXCNESJKXFY-UHFFFAOYSA-N 0.000 description 1
- 102220629576 All-trans-retinol dehydrogenase [NAD(+)] ADH4_K4M_mutation Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038381 Renal atrophy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- -1 hydroxypropyl methyl Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
The invention relates to a MT-1207 hydrochloride sustained-release preparation, a preparation method and an application thereof, wherein the sustained-release preparation comprises the following components in parts by weight: 30 parts of MT-1207 hydrochloride; 50-120 parts of D-lactose monohydrate; 0-40 parts of polyvinylpyrrolidone; 40-80 parts of hydroxypropyl methyl cellulose; 1-50 parts of ethyl cellulose;
0-80 parts of SR and 0.5-1.5 parts of ferric trioxide; 2-8 parts of silicon dioxide; 0.2-0.8 part of magnesium stearate; the structural formula of the MT-1207 hydrochloride is shown as a formula (I). MT-1207 hydrochloride in the hydrochloride sustained release preparation can be continuously released within 24 hours in one day in an in vitro testThe release of MT-1207 can meet the requirement of slow release.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a MT-1207 hydrochloride sustained-release preparation as well as a preparation method and application thereof.
Background
MT-1207 hydrochloride has the advantages of definite antihypertensive effect, quick response, mild heart rate slowing down accompanied by antihypertensive, no influence on a heart conduction system, favorable influence on hemodynamics and protective effect on organ damage caused by hypertension after long-term administration. MT-1207 hydrochloride preferably has the effect of ensuring the effective level of MT-1207 hydrochloride in plasma after the medicament is absorbed through gastrointestinal tracts and can continuously show linear dissolution within 24 hours a day. However, the MT-1207 hydrochloride preparation in the prior art cannot meet the requirement of slow release. Therefore, the prescription of MT-1207 hydrochloride formulations needs to be optimized to meet the requirement of sustained release once a day dosing.
Disclosure of Invention
In view of the above, the invention aims to provide an MT-1207 hydrochloride sustained-release preparation, and a preparation method and an application thereof, wherein the MT-1207 hydrochloride sustained-release preparation can ensure that MT-1207 hydrochloride can be continuously dissolved within 24 hours a day when dissolved.
Based on the above purpose, one aspect of the present invention provides an MT-1207 hydrochloride sustained release preparation, which comprises the following components in parts by weight:
wherein the weight average molecular weight of the polyvinylpyrrolidone is 35,000-54,000, the weight average molecular weight of the hydroxypropyl methylcellulose is 550,000-650,000, and the particle size of the silicon dioxide is 1-100 mu m;
wherein the structural formula of the MT-1207 hydrochloride is shown as the formula (I):
in a preferred embodiment of the present invention, the amount of MT-1207 hydrochloride is in the following relationship with the amounts of polyvinylpyrrolidone and hydroxypropylmethylcellulose (in parts by weight in the aforementioned ratio, hereinafter the same):
in a preferred embodiment of the invention, the amount of silicon dioxide is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
more preferably, the amount of silica is related to the amount of polyvinylpyrrolidone and hydroxypropyl methylcellulose as follows:
further preferably, the amount of silicon dioxide is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
in a preferred embodiment of the invention, the MT-1207 hydrochloride sustained-release preparation comprises the following components in parts by weight:
more preferably, the hydrochloride sustained-release preparation comprises the following components in parts by weight:
in a preferred embodiment of the invention, the sustained-release preparation of MT-1207 hydrochloride is a tablet, a capsule, a granule, a powder, a pill or a film agent.
Based on the same inventive concept, another aspect of the present invention provides a method for preparing the above-described MT-1207 hydrochloride sustained-release preparation, comprising the steps of:
MT-1207 hydrochloride, silicon dioxide, D-lactose monohydrate,
SR or polyvinylpyrrolidone, and hydroxypropyl methylcellulose, optionally ethyl cellulose and ferric oxide, stirring, dripping one solvent selected from acetonitrile, isopropanol or ethanol into the powdery mixture, and stirring to obtain a wet mixed material;
sieving the mixed wet material for the first time, and then drying to obtain dried particles;
sieving the dried granules for the second time in a mode of gradually increasing the sieving mesh number to obtain sieved granules;
mixing the sieved granules with magnesium stearate, and stirring to obtain a granular mixture;
and (3) performing one-step compression on the mixture by a rotary tablet press to prepare a single-layer tablet, or performing two-step compression to prepare a double-layer tablet, thus obtaining the MT-1207 hydrochloride sustained-release preparation.
In a preferred embodiment of the present invention, the step of obtaining the mixed wet material comprises:
mixing the MT-1207 hydrochloride and silicon dioxide co-powder with D-lactose monohydrate for 2-8 min, and adding
SR or polyvinylpyrrolidone, hydroxypropyl methylcellulose, optionally ethyl cellulose and ferric oxide are mixed for 10-20 min to form a mixture, and one solvent selected from acetonitrile, isopropanol or ethanol is added into the mixture to obtain a mixed wet material;
the mass-volume ratio of the MT-1207 hydrochloride to the solvent is (4-6): 1, and the unit is mg/mL.
In a preferred embodiment of the present invention, the method for preparing the above-mentioned sustained-release preparation of MT-1207 hydrochloride further comprises the steps of:
and (3) performing two-step compression on the mixture by a rotary tablet press to prepare a double-layer tablet, thus obtaining the tablet of the MT-1207 hydrochloride sustained-release preparation.
In a preferred embodiment of the present invention, the mesh number of the first sieving is 10 to 14 meshes;
and/or drying for 1-3 h at 50-70 ℃;
and/or, the second sieving is carried out by sequentially sieving with 20-30 meshes, 40-50 meshes and 140-200 meshes of screens;
and/or mixing the sieved particles with magnesium stearate for 2-8 min.
Based on the same inventive concept, the invention further provides the application of the MT-1207 hydrochloride sustained-release preparation in preparing medicines for preventing, treating and delaying hypertension, target organ damage caused by the hypertension and hypertension-related diseases.
From the above, the invention provides a hydrochloride sustained release preparation, a preparation method and an application thereof, wherein MT-1207 hydrochloride in the hydrochloride sustained release preparation can continuously release MT-1207 within 24 hours a day in an in vitro test, so that the sustained release requirement can be achieved, and the effective level of the MT-1207 hydrochloride in blood plasma after the medicine is absorbed through gastrointestinal tracts can be ensured.
Drawings
FIG. 1 shows the in vitro dissolution of MT-1207 hydrochloride from comparative examples and examples 1, 2, 3 and 4 according to the present invention; wherein an in vitro dissolution curve is plotted with time (h) as the abscissa and the dissolution rate of MT-1207 as the ordinate.
Detailed Description
It is to be noted that unless otherwise defined, technical or scientific terms used in one or more embodiments of the present specification should have the ordinary meaning as understood by those of ordinary skill in the art to which this disclosure belongs.
In the present invention, unless otherwise specified, all operations are carried out under ambient temperature and pressure conditions.
In the present invention, the content ratio between the components in the preparation is by weight unless otherwise specified.
As described in the background section, MT-1207 hydrochloride has the advantages of definite antihypertensive effect, quick response, mild heart rate slowing down accompanied by hypotension, no influence on a heart conduction system, favorable influence on hemodynamics and protective effect on organ damage caused by hypertension after long-term administration. MT-1207 hydrochloride can be ensured to continuously reach the effective level in 24 hours a day after the medicament is absorbed by gastrointestinal tracts when the medicament exerts the medicament effect, so that the effect of once-a-day administration is achieved, and the aim of slowly releasing the MT-1207 hydrochloride preparation is required. However, the MT-1207 hydrochloride preparation in the prior art cannot meet the requirement of slow release. Therefore, the prescription of MT-1207 hydrochloride preparation needs to be optimized to meet the requirement of slow release.
Hydroxypropyl methylcellulose (HPMC) K series have different specifications of K4M, K15M, and K35M, HPMC of different specifications have different weight average molecular weights, for example HPMC K4M has a weight average molecular weight of 400,000; HPMC K15M has a weight average molecular weight of 575,000; HPMC K35M had a weight average molecular weight of 675,000, both available from Kaschin-Nash chemical (Nanjing) Ltd.
The inventors of the present invention tried to replace HPMC K4M with HPMC K15M in the prior art MT-1207 hydrochloride formulation and found that the dissolution rate was significantly slowed. The inventors of the present invention continued to attempt to join
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), it was also found that the dissolution rate was significantly slowed. On the basis, the inventor determines the prescription of the MT-1207 hydrochloride sustained-release preparation provided by the invention through a large number of tests, and carries out in-vitro dissolution test and in-vivo pharmacokinetic test, and the dissolution test result shows that the MT-1207 hydrochloride sustained-release preparation provided by the invention is usedIn the formula, the MT-1207 hydrochloride of the MT-1207 hydrochloride sustained-release preparation is continuously dissolved within 24 hours a day, the sustained-release requirement can be met, and the effective level of the MT-1207 hydrochloride in blood plasma after the medicament is absorbed by gastrointestinal tracts can be ensured.
The invention provides an MT-1207 hydrochloride sustained-release preparation, which comprises the following components in parts by weight:
the MT-1207 hydrochloride sustained-release preparation comprises the following components in parts by weight:
wherein the weight average molecular weight of the polyvinylpyrrolidone is 35,000-54,000, the weight average molecular weight of the hydroxypropyl methylcellulose is 550,000-650,000, preferably 570,000-600,000, and the particle size of the silicon dioxide is 1-100 μm;
wherein the structural formula of the MT-1207 hydrochloride is shown as the formula (I):
chemical name of MT-1207 hydrochloride: 3- (4- (4- (1H-benzotriazol-1-yl) butyl) piperazin-1-yl) benzisothiazole hydrochloride of the formula: c21H24SN6HCl, molecular weight: 428.98, the appearance is white powder.
In a preferred embodiment of the invention, the amount of MT-1207 hydrochloride is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
in a preferred embodiment of the invention, the amount of silicon dioxide is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
more preferably, the amount of silica is related to the amount of polyvinylpyrrolidone and hydroxypropyl methylcellulose as follows:
further preferably, the amount of silicon dioxide is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
in a preferred embodiment of the invention, the MT-1207 hydrochloride sustained-release preparation comprises the following components in parts by weight:
more preferably, the hydrochloride sustained-release preparation comprises the following components in parts by weight:
it should be noted that the technical problems to be solved by the present invention can be solved by the prescription of the sustained-release hydrochloride preparation provided by the present invention through experimental verification, and MT-1207 hydrochloride can be continuously released within 24 hours a day in dissolution. In the formulation of the sustained-release hydrochloride preparation provided by the present invention, example 2 is a preferred example of the sustained-release hydrochloride preparation of the present invention, and MT-1207 hydrochloride in the tablet prepared in example 2 is continuously linearly dissolved for 24 hours. This is most desirable because it ensures a constant effective level of MT-1207 hydrochloride in the plasma after absorption of the drug through the gastrointestinal tract.
In the present invention, the name of D-lactose monohydrate can also be D-lactose (monohydrate) or α -D-lactose (monohydrate), specifically: O-beta-D-galactopyranosyl- (1 → 4) -alpha-D-glucopyranose monohydrate, formula C12H22O11H2O, molecular weight 360.13, available from the limited noble company of michelil chemical technology, shanghai.
Polyvinylpyrrolidone (PVP) includes species K15, K30, K60 and K90, different PVP species having different weight average molecular weights, for example PVP K30 having a weight average molecular weight of 35,000 to 54,000 are available from guangzhou global-oriented biochemical limited.
The silicon dioxide is a medicinal auxiliary material silicon dioxide, has the particle size of 1-100 mu m, and is purchased from Zhejiang Uwei pharmaceutical industry Co.
The magnesium stearate of the present invention is purchased from Zhejiang Uwei pharmaceutical industries, Inc.
The components of the sustained-release preparation are mixed and then prepared into any pharmaceutically acceptable dosage form according to a conventional preparation method. The dosage form is tablet, capsule, granule, powder, pill or pellicle. More preferably, the sustained release preparation is a tablet, and each sustained release preparation of MT-1207 contains 15-30 mg of MT-1207 hydrochloride.
As described above, the components of the hydrochloride sustained release preparation of the present invention are mixed and then made into any pharmaceutically acceptable dosage form according to the conventional preparation method, more preferably, the dosage form of the hydrochloride sustained release preparation is a tablet, and the tablet is prepared by mixing the raw materials and the auxiliary materials to form a total mixed powder and then directly tabletting the total mixed powder. In order to ensure that the raw and auxiliary materials can be uniformly dispersed in the tablet, the direct compression has high requirement on the fluidity of the total mixed powder. Referring to the information related to the United states pharmacopoeia, the inventor of the invention evaluates the fluidity of the total mixed powder of the MT-1207 hydrochloride preparation in the prior art, and finds that the fluidity can not meet the requirement. Therefore, the inventors tried to improve the flowability of the total powder blend of MT-1207 hydrochloride by wet granulation.
Based on the same inventive concept, another aspect of the present invention provides a method for preparing the above-described MT-1207 hydrochloride sustained-release preparation, comprising the steps of:
the polyethylene oxide 8M is mixed with the polyethylene oxide,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), spray-dried lactose, hydroxypropyl methylcellulose K100M, and silicon dioxide by mixing for 15min, adding magnesium stearate into the mixture, and further mixing for 5min to obtain gastric retention layer;
mixing one solvent selected from acetonitrile, isopropanol or ethanol with MT-1207 hydrochloride, silicon dioxide, D-lactose monohydrate, polyvinylpyrrolidone and hydroxypropyl methyl cellulose to obtain a mixed wet material;
sieving the mixed wet material for the first time, and then drying to obtain dried particles;
sieving the dried granules for the second time in a mode of gradually increasing the sieving mesh number to obtain sieved granules;
and mixing the sieved granules with magnesium stearate, and paving the mixture on a gastric retention layer to obtain the MT-1207 hydrochloride sustained-release preparation.
In wet granulation, a wide variety of organic solvents may be used to help modify the particle size for increased flowability. In the present invention, granulation is first performed using water as a solvent, but agglomeration occurs during mixing, and then one of acetonitrile, isopropanol or ethanol is used as a solvent, according to the U.S. pharmacopoeia <467>, isopropanol is a low-toxic substance, and is classified as a third type of solvent.
In a preferred embodiment of the present invention, the step of obtaining the mixed wet material comprises:
mixing the MT-1207 hydrochloride and silicon dioxide co-powder with D-lactose monohydrate for 2-8 min, adding polyvinylpyrrolidone and hydroxypropyl methylcellulose, mixing for 10-20 min to form a mixture, and adding one solvent selected from acetonitrile, isopropanol or ethanol into the mixture to obtain a mixed wet material;
the mass-volume ratio of the MT-1207 hydrochloride to the solvent is (4-6): 1, and the unit is mg/mL.
In a preferred embodiment of the present invention, the method for preparing the above-mentioned sustained-release preparation of MT-1207 hydrochloride further comprises the steps of:
the polyethylene oxide 8M is mixed with the polyethylene oxide,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), spray-dried lactose, hydroxypropyl methylcellulose K100M, silicon dioxide were mixed for 15min, magnesium stearate was added to the mixture, and further mixed for 5min to obtain a gastric retentive layer.
And (3) spreading the sieved mixture of granules and magnesium stearate on a gastric retention layer for two-step tabletting to obtain the tablet of the MT-1207 hydrochloride sustained-release preparation.
In a preferred embodiment of the present invention, the mesh number of the first sieving is 10 to 14 meshes, more preferably, the mesh number is 12 meshes;
and/or the drying condition is drying for 1-3 h at 50-70 ℃, more preferably drying for 2h at 60 ℃;
and/or, the second sieving is carried out by sequentially sieving with 20-30 meshes, 40-50 meshes and 140-200 meshes of screens; more preferably, the second sieving is performed by using 25-mesh, 45-mesh and 170-mesh sieves in sequence, and then the percentage content of the granules with the particle size of less than 90 μm in the sieved granules is 3-10%, the percentage content of the granules with the particle size of less than 315 μm in the granules with the particle size of less than 90 μm in the sieved granules is 32-46%, and the percentage content of the granules with the particle size of more than 315 μm in the sieved granules is 48-62%; the majority of the particles with a particle size of > 315 μm, and the proportion below 10% probably contributes to the flowability and compression moldability of the total blend.
And/or mixing the sieved granules and magnesium stearate for 2-8 min, and more preferably mixing for 5 min.
In the present invention, the co-powder refers to a mixture obtained by micronizing MT-1207 hydrochloride and silicon dioxide to a raw material particle size of < 10 μm.
In the present invention, the total blend powder refers to the mixture of all components before tableting.
The MT-1207 hydrochloride sustained-release preparation provided by the invention can be subjected to tabletting after optimized wet granulation to obtain tablets. The inventors of the present invention tried to add hydroxypropylmethylcellulose (HPMC K15M) as a sustained release agent after size stabilization, and then tabletting. The content uniformity, flowability, hardness, and in vitro dissolution (UPS dissolution apparatus, 0.1M phosphate, pH 6.8, 0.2% w/v sodium dodecyl) of MT-1207 tablets (comparative example) were tested according to the United states pharmacopoeia. The tablets of the comparative examples achieved the maximum dissolution rate within 12h and did not achieve the sustained release purpose, when added
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%) and reducing the amount of D-lactose monohydrate and polyvinylpyrrolidone (example 1), the dissolution rate was significantly slowed. Through optimization studies, one formulation of the MT-1207 tablet (example 2) can not only meet the requirement of sustained release, but is also optimal because it can ensure a constant effective level of MT-1207 hydrochloride in plasma after the drug is absorbed through the gastrointestinal tract and can be continuously dissolved within 24 hours, and examples 3 and 4 can also meet the requirement of sustained release, although not optimal, and can also ensure that MT-1207 can be continuously dissolved within 24 hours, and the MT-1207 hydrochloride in plasma can be continuously kept at an effective level after the drug is absorbed through the gastrointestinal tract.
Based on the same inventive concept, the invention further provides the application of the hydrochloride sustained-release preparation in preparing medicines for preventing, treating and delaying hypertension, target organ damage caused by the hypertension and hypertension-related diseases.
In a preferred embodiment of the invention, the target organ injury is hypertension-induced damage to the heart, brain, kidney or blood vessels; the hypertension related diseases comprise atherosclerosis, hyperlipemia, obesity, coronary heart disease, aortic dissection and hyperglycemia, abnormal sugar tolerance, metabolic syndrome and diabetes.
In a preferred embodiment of the invention, the target organ damage is left ventricular hypertrophy, stroke, renal cortex atrophy or aortic thickening, angina, myocardial infarction, heart failure, renal failure, retinal arteriosclerosis, hypertensive fundus oculi disease.
The technical solution provided by the present invention is further described below with reference to specific examples and comparative examples. The following examples are merely illustrative of the present invention and are not intended to limit the scope of the present invention.
The molecular weight of the polymer was measured as a weight average molecular weight by Gel Permeation Chromatography (GPC) according to the national Standard for people's republic of China GB/T21863-2008 (equivalent to German Standard DIN55672-1:2007 section 1 of Gel Permeation Chromatography (GPC) using Tetrahydrofuran (THF) as an eluting solvent).
The following examples relate to formulations summarized in table 1.
Table 1: formulation of MT-1207 hydrochloride tablet
Example 1
Dosage of the single-layer tablet raw material medicine and the auxiliary materials: MT-1207 hydrochloride 30mg, D-lactose monohydrate 75mg, hydroxypropyl methylcellulose K15M70mg,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), 45mg of silicon dioxide 6mg and magnesium stearate 05mg, total weight 226.5 mg.
The preparation method of the MT-1207 hydrochloride sustained-release preparation comprises the following steps:
mixing MT-1207 hydrochloride and silicon dioxide powder with D-lactose for 5min, adding adjuvant such as hydroxypropyl methylcellulose K15M,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium dodecyl sulfate 0.8%), mixing for 15min, and manually adding 4mL of isopropanol into the mixture to obtain a mixed wet material;
manually sieving the mixed wet material by a 12-mesh standard sieve, then flatly paving the mixed wet material in a tray, and drying the mixed wet material in a blast drier under the conditions of 60 ℃ and 2 hours to obtain dried particles;
sieving the dried granules by using screens of 25 meshes, 45 meshes and 170 meshes successively to remove the granules larger than 170 meshes to obtain the sieved granules;
mixing the sieved granulate with magnesium stearate for 5min, followed by tabletting using a Piccola rotary tablet press (
Argentina) to give a mono-layer tablet.
Example 2
Dosage of gastric retention layer auxiliary materials: polyethylene oxide 8M380mg was added,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), 228mg of spray-dried lactose, 47mg of hydroxypropyl methylcellulose K100M16.2mg, 1.5mg of silicon dioxide, and 1.5mg of magnesium stearate.
The polyethylene oxide 8M is mixed with the polyethylene oxide,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium dodecyl sulfate 0.8%), spray-dried lactose, and hydroxypropyl methyl celluloseVitamin K100M, silica were mixed for 15min, magnesium stearate was added to the mixture, and further mixed for 5 min.
The dosage of the raw material medicine and the auxiliary material of the slow-release medicine layer is as follows: MT-1207 hydrochloride 30mg, D-lactose monohydrate 74mg, hydroxypropyl methylcellulose K15M70mg,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium dodecyl sulfate 0.8%), 45mg, ferric oxide 1mg, silicon dioxide 6mg, magnesium stearate 0.5mg, and total weight 226.5 mg.
The preparation method of the MT-1207 hydrochloride sustained-release preparation comprises the following steps:
mixing MT-1207 hydrochloride and silicon dioxide powder with D-lactose for 5min, adding adjuvant such as poly hydroxypropyl methylcellulose K15M,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium dodecyl sulfate 0.8%) and ferric oxide, mixing for 15min, and manually adding 4mL of isopropanol into the mixture to obtain a mixed wet material;
manually sieving the mixed wet material by a 12-mesh standard sieve, then flatly paving the mixed wet material in a tray, and drying the mixed wet material in a blast drier under the conditions of 60 ℃ and 2 hours to obtain dried particles;
sieving the dried granules by using screens of 25 meshes, 45 meshes and 170 meshes successively to remove the granules larger than 170 meshes to obtain the sieved granules;
mixing the sieved granulate with magnesium stearate for 5min, followed by a two-step tabletting operation using a Piccola rotary tablet press (
Argentina) firstly adding the gastric retention powder (namely the mixture of auxiliary materials of the gastric retention layer) into a mould for pre-compression, then adding a granular drug layer (namely a slow-release drug layer) on the gastric retention powder layer, and further compressing to obtain the double-layer tablet.
Example 3
Dosage of gastric retention layer auxiliary materials: polyethylene oxide 8M380mg was added,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), 228mg of spray-dried lactose, 47mg of hydroxypropyl methylcellulose K100M16.2mg, 1.5mg of silicon dioxide, and 1.5mg of magnesium stearate.
The polyethylene oxide 8M is mixed with the polyethylene oxide,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), spray dried lactose, hydroxypropyl methylcellulose K100M, silicon dioxide were mixed for 15min, magnesium stearate was added to the mixture, and further mixed for 5 min.
The dosage of the raw material medicine and the auxiliary material of the slow-release medicine layer is as follows: MT-1207 hydrochloride 30mg, D-lactose monohydrate 65mg, polyvinylpyrrolidone K3020 mg, hydroxypropylmethylcellulose K15M60mg, ethylcellulose 5mg, ferric oxide 1mg, silicon dioxide 6mg, magnesium stearate 0.5mg, total weight 187.5 mg.
The preparation method of the MT-1207 hydrochloride sustained-release preparation comprises the following steps:
mixing MT-1207 hydrochloride, silicon dioxide powder and D-lactose for 5min, adding auxiliary materials of polyvinylpyrrolidone K30, hydroxypropyl methylcellulose K15M, ethyl cellulose and ferric oxide, mixing for 15min, and manually adding 4mL of isopropanol into the mixture to obtain a mixed wet material;
manually sieving the mixed wet material by a 12-mesh standard sieve, then flatly paving the mixed wet material in a tray, and drying the mixed wet material in a blast drier under the conditions of 60 ℃ and 2 hours to obtain dried particles;
sieving the dried granules by using screens of 25 meshes, 45 meshes and 170 meshes successively to remove the granules larger than 170 meshes to obtain the sieved granules;
mixing the sieved granules with magnesium stearate for 5min, and tabletting with a Piccola rotary tablet pressTwo-stage sheeting operation (
Argentina) firstly adding the gastric retention powder (namely the mixture of auxiliary materials of the gastric retention layer) into a mould for pre-compression, then adding a granular drug layer (namely a slow-release drug layer) on the gastric retention powder layer, and further compressing to obtain the double-layer tablet.
Example 4
The difference between this example and example 3 is only that the amounts of D-lactose monohydrate, hydroxypropylmethylcellulose K15M and ethylcellulose are different, and the rest are the same, specifically:
dosage of gastric retention layer auxiliary materials: polyethylene oxide 8M380mg was added,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), 228mg of spray-dried lactose, 47mg of hydroxypropyl methylcellulose K100M16.2mg, 1.5mg of silicon dioxide, and 1.5mg of magnesium stearate.
The polyethylene oxide 8M is mixed with the polyethylene oxide,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium lauryl sulfate 0.8%), spray dried lactose, hydroxypropyl methylcellulose K100M, silicon dioxide were mixed for 15min, magnesium stearate was added to the mixture, and further mixed for 5 min.
The dosage of the raw material medicine and the auxiliary material of the slow-release medicine layer is as follows: 30mg of MT-1207 hydrochloride, 99mg of D-lactose monohydrate, K3020 mg polyvinylpyrrolidone, K15M70mg hydroxypropyl methylcellulose, 1mg of ferric oxide, 6mg of silicon dioxide, 0.5mg of magnesium stearate, and 226.5mg of the total weight.
The preparation method of the MT-1207 hydrochloride sustained-release preparation comprises the following steps:
mixing MT-1207 hydrochloride, silicon dioxide powder and D-lactose for 5min, adding auxiliary materials of polyvinylpyrrolidone K30, hydroxypropyl methylcellulose K15M, ethyl cellulose and ferric oxide, mixing for 15min, and manually adding 4mL of isopropanol into the mixture to obtain a mixed wet material;
manually sieving the mixed wet material by a 12-mesh standard sieve, then flatly paving the mixed wet material in a tray, and drying the mixed wet material in a blast drier under the conditions of 60 ℃ and 2 hours to obtain dried particles;
sieving the dried granules by using screens of 25 meshes, 45 meshes and 170 meshes successively to remove the granules larger than 170 meshes to obtain the sieved granules;
mixing the sieved granulate with magnesium stearate for 5min, followed by a two-step tabletting operation using a Piccola rotary tablet press (
Argentina) firstly adding the gastric retention powder (namely the mixture of auxiliary materials of the gastric retention layer) into a mould for pre-compression, then adding a granular drug layer (namely a slow-release drug layer) on the gastric retention powder layer, and further compressing to obtain the double-layer tablet.
Comparative examples
This comparative example differs from example 4 only in the amounts of ferric oxide and D-lactose monohydrate used, which are in this case single-layer tablets, and the rest are the same, in particular:
the dosage of the raw material medicine and the auxiliary materials is as follows: 30mg of MT-1207 hydrochloride, 100mg of D-lactose monohydrate, 100mg of polyvinylpyrrolidone K3020 mg, 15 mg of hydroxypropyl methylcellulose K15M70mg, 6mg of silicon dioxide, 0.5mg of magnesium stearate and 226.5mg of total weight.
The preparation method of the MT-1207 hydrochloride sustained-release preparation comprises the following steps:
mixing the MT-1207 hydrochloride and silicon dioxide co-powder with D-lactose for 5min, adding auxiliary materials of polyvinylpyrrolidone K30 and hydroxypropyl methyl cellulose K4M, mixing for 15min, and manually adding 4mL of isopropanol into the mixture to obtain a mixed wet material;
manually sieving the mixed wet material by a 12-mesh standard sieve, then flatly paving the mixed wet material in a tray, and drying the mixed wet material in a blast drier under the conditions of 60 ℃ and 2 hours to obtain dried particles;
sieving the dried granules by using screens of 25 meshes, 45 meshes and 170 meshes successively to remove the granules larger than 170 meshes to obtain the sieved granules;
mixing the sieved granulate with magnesium stearate for 5min, followed by tabletting using a Piccola rotary tablet press (
Argentina) to give tablets.
Test examples
This test example compares the tablets prepared in examples 1 to 4 with those prepared in comparative example in terms of in vitro dissolution.
1 method
1.1 in vitro dissolution of MT-1207 tablets
In vitro dissolution A USP II dissolution apparatus (Kopril, Nongham, UK) equipped with a paddle shaft assembly was used at 75rpm, 500mL of 0.1M acetic acid buffer was added to the dissolution apparatus at a pH of 4.0 and a set temperature of 37. + -. 0.5 ℃. In order to prevent the tablet from sticking to the bottom of the vessel, a sedimentation basket was used for dissolution, and 1mL of the supernatant was transferred to a sample bottle and analyzed by HPLC after centrifugation (2300g,10min) at 1h, 2h, 4h, 6h, 8h, 12h, 16h, and 24h after dissolution. In vitro dissolution studies were required for the first, second and third replicates of the tablets of comparative example, examples 1-4, all in triplicate.
2 results
2.1MT-1207 in vitro dissolution test
The in vitro dissolution results of MT-1207 of different sustained release preparations are shown in figure 1. Examples 1, 2, 3, 4 showed complete dissolution of MT-1207 within 12 hours in an in vitro dissolution test compared to the comparative examples, while the remaining sustained release agents extended sustained dissolution of the Active Pharmaceutical Ingredient (API) to more than 24 hours.
Dissolution studies of these four sustained release formulations showed that MT-1207 was released continuously over 24 hours in vivo. The novel sustained-release tablet can ensure gastric retention of the drug in vivo for 24 hours through a gastric retention layer and contribute to sustained release of MT-1207. In addition to this, the present invention is,
SR (polyvinyl acetate 80%, polyvinylpyrrolidone 19%, sodium dodecyl sulfate 0.8%) helps to delay the dissolution of MT-1207 hydrochloride in vivo in a single-layer tablet. Hydrophilic and hydrophobic polymers may have good application prospects in 24-hour sustained release formulations.
Examples 1, 2, 3, 4 four sustained release formulations are believed to be available for once-a-day oral administration of MT-1207 hydrochloride.
Claims (10)
1. The MT-1207 hydrochloride sustained-release preparation is characterized by comprising the following components in parts by weight:
wherein,
SR comprises 80% of polyvinyl acetate, 19% of polyvinylpyrrolidone and 0.8% of lauryl sodium sulfate;
the weight average molecular weight of the polyvinylpyrrolidone is 35,000-54,000, the weight average molecular weight of the hydroxypropyl methyl cellulose is 550,000-650,000, and the particle size of the silicon dioxide is 1-100 mu m;
wherein the structural formula of the MT-1207 hydrochloride is shown as the formula (I):
2. the sustained-release preparation of MT-1207 hydrochloride according to claim 1, wherein the amount of MT-1207 hydrochloride is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
3. the sustained-release formulation of MT-1207 hydrochloride according to claim 1 or 2, wherein the amount of silicon dioxide is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
more preferably, the amount of silica is related to the amount of polyvinylpyrrolidone and hydroxypropyl methylcellulose as follows:
further preferably, the amount of silicon dioxide is related to the amount of polyvinylpyrrolidone and hydroxypropylmethylcellulose as follows:
4. the sustained-release preparation of MT-1207 hydrochloride according to any one of claims 1 to 3, wherein the sustained-release preparation of MT-1207 hydrochloride comprises the following components in parts by weight:
more preferably, the MT-1207 hydrochloride sustained-release preparation comprises the following components in parts by weight:
5. the sustained-release preparation of MT-1207 hydrochloride according to any one of claims 1 to 4, wherein the sustained-release preparation of MT-1207 hydrochloride is a tablet, capsule, granule, powder, pill or film.
6. A process for the preparation of a sustained release formulation of MT-1207 hydrochloride according to any of claims 1 to 5, comprising the steps of:
MT-1207 hydrochloride, silicon dioxide, D-lactose monohydrate,
SR or polyvinylpyrrolidone, and hydroxypropyl methylcellulose, optionally ethyl cellulose and ferric oxide, stirring, dripping one solvent selected from acetonitrile, isopropanol or ethanol into the powdery mixture, and stirring to obtain a wet mixed material;
sieving the mixed wet material for the first time, and then drying to obtain dried particles;
sieving the dried granules for the second time in a mode of gradually increasing the sieving mesh number to obtain sieved granules;
mixing the sieved granules with magnesium stearate, and stirring to obtain a granular mixture;
and (3) performing one-step compression on the mixture by a rotary tablet press to prepare a single-layer tablet, or performing two-step compression to prepare a double-layer tablet, thus obtaining the MT-1207 hydrochloride sustained-release preparation.
7. The method of claim 6, wherein the step of obtaining a wet mix comprises:
mixing MT-1207 hydrochloride and silicon dioxide co-powder and D-lactose monohydrateMixing for 2-8 min, and adding
SR or polyvinylpyrrolidone, hydroxypropyl methylcellulose, optionally ethyl cellulose and ferric oxide are mixed for 10-20 min to form a mixture, and one solvent selected from acetonitrile, isopropanol or ethanol is added into the mixture to obtain a mixed wet material;
the mass-volume ratio of the MT-1207 hydrochloride to the solvent is (4-6): 1, and the unit is mg/mL.
8. The method for preparing an MT-1207 hydrochloride sustained release formulation according to claim 6 or 7, further comprising the steps of:
mixing the wet mixture with magnesium stearate, adding into a mold, pre-compressing with a rotary tablet press, adding the granular drug layer on the pre-compressed granular powder, and gradually increasing the compression force to obtain the tablet of the MT-1207 hydrochloride sustained release preparation.
9. The method for preparing an MT-1207 hydrochloride sustained release preparation according to one of claims 6 to 8, wherein the mesh number of the first sieving is 10 to 14 meshes;
and/or drying for 1-3 h at 50-70 ℃;
and/or, the second sieving is carried out by sequentially sieving with 20-30 meshes, 40-50 meshes and 140-200 meshes of screens;
and/or mixing the sieved particles with magnesium stearate for 2-8 min.
10. Use of the sustained-release MT-1207 hydrochloride preparation according to any one of claims 1 to 5 for the preparation of a medicament for the prevention, treatment and delay of hypertension, target organ damage caused by hypertension and hypertension-related diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210108925.2A CN114209669A (en) | 2022-01-28 | 2022-01-28 | Sustained-release preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210108925.2A CN114209669A (en) | 2022-01-28 | 2022-01-28 | Sustained-release preparation and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114209669A true CN114209669A (en) | 2022-03-22 |
Family
ID=80708800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210108925.2A Pending CN114209669A (en) | 2022-01-28 | 2022-01-28 | Sustained-release preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114209669A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115304593A (en) * | 2022-09-19 | 2022-11-08 | 皮摩尔新药(辽宁)有限公司 | Benzisothiazole compound, and pharmaceutical composition and application thereof |
| CN115381827A (en) * | 2022-09-19 | 2022-11-25 | 皮摩尔新药(辽宁)有限公司 | Application of benzotriazole alkyl derivative in preparation of medicine for treating or preventing cardiovascular diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113712929A (en) * | 2020-05-26 | 2021-11-30 | 沈阳海王生物技术有限公司 | MT-1207 hydrochloride sustained-release preparation and preparation method and application thereof |
-
2022
- 2022-01-28 CN CN202210108925.2A patent/CN114209669A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113712929A (en) * | 2020-05-26 | 2021-11-30 | 沈阳海王生物技术有限公司 | MT-1207 hydrochloride sustained-release preparation and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| VRETTOS,ET AL: "In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207", 《PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115304593A (en) * | 2022-09-19 | 2022-11-08 | 皮摩尔新药(辽宁)有限公司 | Benzisothiazole compound, and pharmaceutical composition and application thereof |
| CN115381827A (en) * | 2022-09-19 | 2022-11-25 | 皮摩尔新药(辽宁)有限公司 | Application of benzotriazole alkyl derivative in preparation of medicine for treating or preventing cardiovascular diseases |
| CN115381827B (en) * | 2022-09-19 | 2024-02-06 | 皮摩尔新药(辽宁)有限公司 | Application of benzotriazole derivative in preparation of medicine for treating or preventing cardiovascular diseases |
| CN115304593B (en) * | 2022-09-19 | 2024-02-23 | 皮摩尔新药(辽宁)有限公司 | Benzisothiazole compound, and pharmaceutical composition and application thereof |
| WO2024060911A1 (en) * | 2022-09-19 | 2024-03-28 | 皮摩尔新药(辽宁)有限公司 | Benzoisothiazole compound, and pharmaceutical composition and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110548148B (en) | Pharmaceutical composition containing glucokinase activator and SGLT-2 inhibitor and preparation method and application thereof | |
| JP6122098B2 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof | |
| US8435564B2 (en) | Pharmaceutical compositions comprising brivaracetam | |
| CN114209669A (en) | Sustained-release preparation and preparation method and application thereof | |
| EP1738754B1 (en) | Solid pharmaceutical preparation | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| TW201545745A (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition | |
| JP2017523149A (en) | Edoxaban pharmaceutical composition | |
| WO2021254409A1 (en) | Pharmaceutical composition of complex and preparation method therefor | |
| EP3697392B1 (en) | Tablets comprising tamsulosin and solifenacin | |
| WO2022115056A1 (en) | Sustained release formulation compositions comprising propiverine | |
| CN113712929A (en) | MT-1207 hydrochloride sustained-release preparation and preparation method and application thereof | |
| CA2893480C (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
| JP2011527316A (en) | Aliskiren tablets by direct compression | |
| TWI415604B (en) | Controlled release carvediolol formulation | |
| RU2770043C9 (en) | Pharmaceutical combination, composition, and combined combination containing a glucokinase activator and an sglt-2 inhibitor, and methods for production and application thereof | |
| RU2772875C1 (en) | Pharmaceutical combination, composition, and combined formulation containing a glucokinase activator and a katp channel blocker, method for production and application thereof | |
| KR100804829B1 (en) | Pharmaceutical compositions for oral administration containing nateglinide | |
| CN115381788A (en) | Tofacitinib citrate preparation and preparation method thereof | |
| EP2846778B1 (en) | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate | |
| WO2013007360A1 (en) | Controlled release pharmaceutical composition of non-ergoline dopamine agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |